COVID-19HypercovidNCT05224830
Relationship Between Hyperventilation Syndrome and SARS-CoV-2 Infection
An observational study of COVID-19 and Hyperventilation Syndrome, run by Central Hospital, Nancy, France at 1 site in France.
Trial summary
Following an acute COVID-19 infection, many patients suffer from long lasting physical symptoms that may greatly impair quality of life. Persisting dyspnea and other functional respiratory complaints could evoke Hyperventilation Syndrome (HVS) as a putative contributor of the long-COVID presentation in COVID-19… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COVID-19, Hyperventilation Syndrome
- What is being tested?
- Nijmegen questionnaire score
- How many people
- 2,846 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2021to 1 Jul 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The inclusion criteria were age greater than 18 years old, with the ability to perform a pulmonary function test in our Lung Function and Exercise Testing Department. Eligible patients were able to read and speak French in order to correctly answer to the self-reported questionnaire. The exclusion criteria were incomplete questionnaire or inability to obtain an interpretable lung function assessment.
Who may be able to join
- Read and speak French
- Perform a pulmonary function test
Who cannot join
- incomplete questionnaire or inability to obtain an interpretable lung function assessment
Trial locations and contacts
1 site in 1 country.
France1 site
Centre Hospitalier Régional Universitaire de Nancy.
Vandœuvre-lès-Nancy, 54500
About this study
Official title: A Cross-sectional Study : Is There a Relationship Between Hyperventilation Syndrome and History of Acute SARS-CoV-2 Infection?
Following an acute COVID-19 infection, many patients suffer from long lasting physical symptoms that may greatly impair quality of life. Persisting dyspnea and other functional respiratory complaints could evoke Hyperventilation Syndrome (HVS) as a putative contributor of the long-COVID presentation in COVID-19 survivors. We aimed to assess the possible relationship between a HVS and previous acute SARS-CoV-2 infection.
- Conditions
- COVID-19, Hyperventilation Syndrome
- Being tested
- Nijmegen questionnaire score
- Keywords
- covid-19, dyspnea, Hyperventilation Syndrome
- Medical subject headings
- COVID-19, Dyspnea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nijmegen questionnaire scoreOther
We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome
| Study group | Role | What they receive |
|---|---|---|
| Presence of Hyperventilation Syndrome (HVS+) | Study population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS +- : Nijmegen questionnaire score > 23/64 Receives: Other: Nijmegen questionnaire score | |
| No presence of Hyperventilation Syndrome (HVS-). | Study population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS - : Nijmegen questionnaire score < 24/64 Receives: Other: Nijmegen questionnaire score |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess the relationship between a hyperventilation syndrome and previous acute SARS-CoV-2 infection.
Measured: Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)
Secondary outcomes (1)
Assess the relationship between a hyperventilation syndrome and dyspnea
Measured: Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2022
- Study start1 Jan 2021
- Primary completion1 May 2022
- Study completion1 Jul 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 2,846 participants (actual)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05224830
- Sponsor's protocol ID
- 2021PI224-203
- Acronym
- Hypercovid
- Status last verified
- Feb 2022
- First submitted
- 3 Feb 2022
- Last updated
- 7 Sep 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Sep 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Cross-sectional Study : Is There a Relationship Between Hyperventilation Syndrome and History of Acute SARS-CoV-2 Infection?
- ClinicalTrials.gov ID
- NCT05224830
- Acronym / sponsor ID
- Hypercovid / 2021PI224-203
- Conditions
- COVID-19, Hyperventilation Syndrome
- Keywords
- covid-19, dyspnea, Hyperventilation Syndrome
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,846 participants (actual)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 1 May 2022 (actual)
- Study completion
- 1 Jul 2022 (actual)
- First posted
- 4 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Following an acute COVID-19 infection, many patients suffer from long lasting physical symptoms that may greatly impair quality of life. Persisting dyspnea and other functional respiratory complaints could evoke Hyperventilation Syndrome (HVS) as a putative contributor of the long-COVID presentation in COVID-19 survivors. We aimed to assess the possible relationship between a HVS and previous acute SARS-CoV-2 infection.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Presence of Hyperventilation Syndrome (HVS+) | – | Other: Nijmegen questionnaire scoreStudy population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS +- : Nijmegen questionnaire score > 23/64 |
| No presence of Hyperventilation Syndrome (HVS-). | – | Other: Nijmegen questionnaire scoreStudy population was divided into two groups according to the diagnosis of Hyperventilation Syndrome HVS - : Nijmegen questionnaire score < 24/64 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The inclusion criteria were age greater than 18 years old, with the ability to perform a pulmonary function test in our Lung Function and Exercise Testing Department. Eligible patients were able to read and speak French in order to correctly answer to the self-reported questionnaire. The exclusion criteria were incomplete questionnaire or inability to obtain an interpretable lung function assessment.
Key inclusion criteria (2 listed)
- Read and speak French
- Perform a pulmonary function test
Key exclusion criteria (1 listed)
- incomplete questionnaire or inability to obtain an interpretable lung function assessment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nijmegen questionnaire scoreWe collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome | Other | No presence of Hyperventilation Syndrome (HVS-)., Presence of Hyperventilation Syndrome (HVS+) |
Primary outcome
Assess the relationship between a hyperventilation syndrome and previous acute SARS-CoV-2 infection.
Time frame: Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)
1 secondary outcome
Assess the relationship between a hyperventilation syndrome and dyspnea
Time frame: Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Sep 2022.
Related trials for COVID-19
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Active, not recruitingObservational study
A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza
COVID-19, Coronavirus Disease 2019
Active, not recruiting
Long COVID Brain Fog: Cognitive Rehabilitation Trial
Long COVID, Brain Fog
Active, not recruitingObservational study
Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
COVID-19 Vaccination
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 and Hyperventilation Syndrome, run by Central Hospital, Nancy, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess the relationship between a hyperventilation syndrome and previous acute SARS-CoV-2 infection. (time frame: Nijmegen questionnaire during 15 minutes (cross-sectional monocentric study)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Sep 2022; AzTrials last refreshed its copy on 30 Oct 2026.